Cargando…
PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis
BACKGROUND: Psoriasis vulgaris is commonly treated with topical corticosteroids and vitamin D analogues. Although potent and super-potent topical corticosteroids are very effective at clearing psoriasis, with short-term reactive treatment durations, symptoms usually recur after treatment discontinua...
Autores principales: | Stein Gold, Linda, Alonso-Llamazares, Javier, Lacour, Jean-Philippe, Warren, Richard B., Tyring, Stephen K., Kircik, Leon, Yamauchi, Paul, Lebwohl, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547957/ https://www.ncbi.nlm.nih.gov/pubmed/32965655 http://dx.doi.org/10.1007/s12325-020-01497-6 |
Ejemplares similares
-
Quality of life and patient‐perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed‐dose combination Cal/BD foam: A post‐hoc analysis of PSO‐LONG
por: Jalili, A., et al.
Publicado: (2021) -
Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study
por: Paul, Carle, et al.
Publicado: (2017) -
Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Characteristics
por: Lebwohl, Mark G., et al.
Publicado: (2021) -
Addressing challenges associated with long‐term topical treatment and benefits of proactive management in patients with psoriasis
por: Lebwohl, M., et al.
Publicado: (2021) -
Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO‐ABLE study
por: Paul, C., et al.
Publicado: (2016)